Clinical Trial Detail

NCT ID NCT04028245
Title A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Charles G. Drake

clear cell renal cell carcinoma

renal cell carcinoma


Canakinumab + Spartalizumab

Age Groups: adult senior

No variant requirements are available.